A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors.
Arkadiusz Z. Dudek(Regions Hospital), J. L. Mesías Iglesias(FuelCell Energy (United States)), Paulette Mattson(FuelCell Energy (United States)), Nandita Bose(FuelCell Energy (United States)), Ben J. Harrison(The University of Melbourne), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Benjamin Lee Kitchens(Baylor University Medical Center), Michele Gargano(FuelCell Energy (United States)), Michael E. Stokes(FuelCell Energy (United States)), Brian H. Rank(HealthPartners), Eric S. Lightcap, Dhamina Karim(FuelCell Energy (United States)), Ashley LaCayo(FuelCell Energy (United States)), David Surguladze(Intellicell Biosciences (United States)), Dipesh Uprety(Wayne State University), Jeremy Drees(FuelCell Energy (United States)), Richard Li(FuelCell Energy (United States)), Thomas E. Hutson(Privolzhsky Research Medical University), Joyce O’Shaughnessy(Baylor University Medical Center), Crissy Dudgeon(Rutgers, The State University of New Jersey)
Cited by 13
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846